VisionGate’s Alan Nelson Named National Academy of Inventors Fellow

Share Article

Nelson Holds 139 Patents for Inventions Related to Early Cancer Detection

News Image
Dr. Nelson’s focus on early cancer detection and his associated inventions epitomize the principles held by our Academy.

VisionGate Founder, Chairman and Chief Executive Officer Alan Nelson, PhD, was recently named a National Academy of Inventors (NAI) 2015 Fellow. Among 168 leaders of invention and innovation from around the world who together account for 5,368 issued U.S. patents, the election to NAI Fellow status is a “high professional distinction accorded to academic inventors who have demonstrated a highly prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and welfare of society”.

“To be honored as an NAI Fellow is an important professional distinction and a symbol of truly innovative, inventive, life-changing work,” NAI President Dr. Paul R. Sanberg said. “Dr. Nelson’s focus on early cancer detection and his associated inventions epitomize the principles held by our Academy.”

Dr. Nelson holds 139 patents, many of which he earned while at the University of Washington where he invented the world’s first machine to automate cervical cancer screening, a technology that is a large part of women’s healthcare today. There, he also developed the Cell-CT, the first technology with the ability to view cells in their true, three-dimensional state allowing for earlier disease detection. Whether at MIT, Harvard, University of Washington, or more recently as the head of Arizona State University’s renowned Biodesign Institute until 2010, he has dedicated his career to developing early cancer detection technologies that improve upon a physician’s ability to detect cancer early when treatment is most effective and when the most lives can be saved.

“The one role Alan has championed over and over has been that of a pioneer in the fight to eradicate cancer through the effective and focused use of technology,” said Citadel Patent Law Founder George Leone. “The sheer number of patents is only surpassed by his deep concern for human health, primarily focused on the eradication of cancer, honesty, transparency, optimism, hard work and perseverance.”

Dr. Nelson was present for the induction into the Academy, which took place in Virginia at the United States Patent and Trademark office.

“Next to the global impact of life-saving cancer detection technologies, this NAI recognition is among my proudest achievements,” Dr. Nelson said. “I am so honored and deeply humbled to be recognized alongside some of the most meritorious inventors in the world today. And I am grateful to be working with teams of like-minded scientists and business professionals who help achieve the impact of invention.”

For more information, please visit http://www.visiongate3d.com or http://www.academyofinventors.org.

###

About VisionGate

VisionGate, Inc. is led by Dr. Alan Nelson, physicist, bioengineer and entrepreneur who previously developed the world’s first and only automated screening test to detect cervical cancer, marketed globally today as FocalPoint by Becton Dickinson. VisionGate’s proprietary LuCED test is a non-invasive diagnostic test for early-stage lung cancer, demonstrating exquisite sensitivity and specificity in blinded clinical studies. This physician-ordered, take-home sputum test is processed on the world’s first 3D cell imaging platform, the Cell-CT, named aptly because it is similar in principle to taking a CT scan of individual cells, but using visible light without harmful radiation. Moreover, with the new exclusive patent license from the University of Colorado for the drug called Iloprost, VisionGate will drive the therapeutic market for chemoprevention of lung cancer and, ultimately, the eradication of this killer. With 141 issued patents in 13 countries, VisionGate expects to play a leading role in the battle against the world’s number one cancer killer.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Shelley Parnell
Visit website